Overview
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-03-01
2024-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of Minnesota
Criteria
Exclusion Criteria:- Pregnancy
Inclusion Criteria:
- Diagnosis of SARS-CoV-2 with first positive test within 14 days, and,
- Diagnosis of ARDS by the Berlin Criteria (2012):
1. Onset: < 7 days
2. Chest x-ray: Bilateral Patchy Opacities, Infiltrates
3. Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O
4. Pulmonary Edema: Not fully explained by cardiogenic etiology
5. Hypoxia: PaO2/FIO2 Ratio < 300, or O2Sat/FIO2 Ratio < 315